VIVO diagnostics buys Genyca and leads the way in precision diagnostics

21/06/2019
Diego Gutiérrez
VIVO diagnostics buys Genyca and leads the way in precision diagnostics

The VIVO diagnóstico group takes a further step on its way to becoming the leading company in precision diagnostics in Spain. The company enters the field of genetics, and has just formalised the incorporation of the Genyca group, a laboratory specialising in molecular genetics.

VIVID DIAGNOSIS

VIVO diagnosis is a company specialising in diagnostic imaging and telemedicineThe new system will be able to combine in vivo and in vitro diagnostics through the use of artificial intelligence and Big Data tools.

To this end, it carries out an analysis based on prediction, prevention and personalisation. For the group, it is essential to identify any signs or probability of change in people's state of health as early as possible and as accurately as possible.

Ahora, además, gracias a Genyca, se va a incorporar pruebas de diagnóstico genético molecular para ayudar a estudiar el genoma de cada individuo, también denominado por algunos líderes del sector como el “software del cuerpo humano”.

However, this is not VIVO diagnostics' first operation on the market. Its journey towards precision diagnostics and service to the public began two years ago with two other operations. acquisitions . The following are some of the issues that we set out below.

Dima Clinic

This clinic leader in breast pathology was the first of these. Dima Clinic has expert breast surgeons, radiologists and oncologists who offer comprehensive breast diagnosis and treatment.

Its experts assess each patient and her risk factors, using both mammography and breast ultrasound and obtaining the analysis of the results in an average of 2-3 days, as in these cases time is of the essence.

Fence

Después vino Cerco, una compañía referente en el mercado andaluz y with a strong presence in the world of clinical research.

In addition to mammography and breast ultrasound, its services include magnetic resonance imaging, CT and densitometry, with the aim of offering patients the highest diagnostic quality and reliability.

Lastest news

Informe de valoración de sector SaaS 2025

Valoración de SaaS en 2025: perspectivas de los mercados públicos El sector SaaS en 2025 presenta un panorama de valoración más realista, aunque cautelosamente optimista. Tras los espectaculares máximos de 2021 y la fuerte corrección de 2022, las valoraciones de las...

Baker Tilly asesora a T2O en su adquisición de Fly Me to the Moon

t2ó ONE, una agencia española especializada en performance marketing y transformación digital, ha anunciado la adquisición de Fly Me to the Moon, una agencia creativa reconocida por su enfoque estratégico e innovador. Esta operación permite a t2ó ampliar sus...

How is technology transforming film and television? | 5 trends

El sector audiovisual está viviendo una revolución silenciosa pero imparable. No se trata solo de efectos especiales más espectaculares o de nuevas plataformas de streaming. Estamos asistiendo a una transformación radical en la forma en que se produce, se distribuye y...

Do you want to sell or buy a company?

We are experts in M&A transactions in the technology sector.

Subscribe to our newsletter

    On which topic would you like to receive information?

    Request for information

    If you want to buy or sell a company, or need more information about our services, do not hesitate to contact us through the form.

    Or if you prefer, call us at:

    +34 946 42 41 42